Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | CASP3 | P42574 | 1/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PLEC | Q15149 | 1/20 | 0.77 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.77 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.77 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 13/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525302 | 1.00 | KDM4E (0.77) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL12275030 | 1.00 | KDM4E (0.77) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL13980482 | 0.90 | KDM4E (0.83) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8806871 | 0.86 | KDM4E (0.77) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8806870 | 0.86 | KDM4E (0.77) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL23785508 | 0.85 | KDM4E (0.76) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7828469 | 0.82 | KDM4E (0.76) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7828471 | 0.82 | KDM4E (0.76) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3824529 | 0.81 | MAOB (0.67) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4299698 | 0.81 | MAOB (0.67) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810038-A | A kind of preparation method of azetidinone class blood lipid-lowering medicine ezetimibe | 南通常佑药业科技有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-109810038-A | A kind of preparation method of azetidinone class blood lipid-lowering medicine ezetimibe | 南通常佑药业科技有限公司 | 2019-05-28 | — | — | CN | disclosed |
| EP-2414326-B1 | INTERMEDIATES IN THE PREPARATION OF 1,4-DIPHENYL AZETIDINONE | LUPIN LTD (IN) | 2017-12-20 | — | — | EP | disclosed |
| EP-2326616-B1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFORE | LEK PHARMACEUTICALS (SI) | 2017-03-08 | — | — | EP | disclosed |
| EP-2326616-B1 | PROCESS FOR THE SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USEFUL THEREFORE | LEK PHARMACEUTICALS (SI) | 2017-03-08 | — | — | EP | disclosed |
| US-9518014-B2 | Process for synthesis of ezetimibe and intermediates used in said process | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-12-13 | — | — | US | disclosed |
| US-20150166479-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-06-18 | — | — | US | disclosed |
| US-9040688-B2 | Intermediates in the preparation of 1,4-diphenyl azetidinone | LUPIN LIMITED (IN) | 2015-05-26 | — | — | US | disclosed |
| CN-102112430-B | Process for synthesis of ezetimibe and intermediates useful therefor | LEK PHARMACEUTICALS | 2014-05-28 | — | — | CN | disclosed |
| WO-2012076030-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE COMPOUNDS USEFUL IN THE PREPARATION OF EZETIMIBE | PHARMATHEN S.A. (GR) | 2012-06-14 | — | — | WO | disclosed |
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT. (HU) | 2009-08-27 | — | — | US | disclosed |
| US-7544667-B2 | Hypocholesterolemic compounds | LIPIDEON BIOTECHNOLOGY AG (CH) | 2009-06-09 | — | — | US | disclosed |
| WO-2009067960-A2 | A METHOD OF MANUFACTURING (3R,4S)-L-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)-3- HYDROXYPROPYL)]-4-(4-HYDROXYPHENYL)-2-AZETIDINONE AND ITS INTERMEDIATES | ZENTIVA, A.S. (CZ) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008106900-A1 | METHOD OF MANUFACTURING (3R, 4S) -1- (4-FLUOROPHENYL) -3- [ (3S) -3- (4 -FLUOROPHENYL) -3-HYDROXYPROPYL) ] -4- (4-HYD ROXYPHENYL) -2-AZETIDINONE | ZENTIVA, A.S. (CZ) | 2008-09-12 | — | — | WO | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| EP-1963260-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008094319-A2 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYTEM (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | LIPIDEON BIOTECHNOLOGY AG (CH) | 2007-11-29 | — | — | US | disclosed |
| WO-2007072088-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166479-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | HMGCR, COASY, APOB | KDM4E 138/4885ALDH1A1 268/4885MEN1 1286/4885 |
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | APOB, HMGCR, PCSK9 | KDM4E 733/4885ALDH1A1 342/4885MEN1 2791/4885 |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | KDM4E 3451/4885ALDH1A1 3768/4885MEN1 392/4885 |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | PCSK9, APOB, HMGCR | KDM4E 3847/4885ALDH1A1 1933/4885MEN1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.